Skip to main content

Table 2 Key dates and relevant protection periods for sofosbuvir, imatinib, and trastuzumab, based on SPCs granted in France [56, 64, 71]

From: Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib

Year of market launch201320011999
Year sales revenue surpassed R&D investment201520032000
Basic patent expiry date26/03/202825/03/201315/06/2012
SPC term> 9 months> 3 years 8 months> 2 years 1 month
SPC expiry date17/01/202921/12/201629/07/2014